Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals

Sebastiaan ter Horst1 | Nádia Conceição-Neto2 | Johan Neyts1 | Joana Rocha-Pereira1

1 Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Leuven, Belgium
2 Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology, KU Leuven, Leuven, Belgium

Correspondence
Joana Rocha-Pereira, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Herestraat 49, Leuven 3000, Belgium. Email: joana.rochapereira@kuleuven.be

Present Address
Nádia Conceição-Neto, Janssens Pharmaceutical Companies of Johnson and Johnson, Beerse, Belgium.

Funding information
Infect-ERA, Grant/Award Number: ESCential

1 INTRODUCTION

Currently, two out of eight “prioritized infectious diseases” by the World Health Organization belong to the order of the Bunyavirusae (previously the family Bunyaviridae), ie, Crimean-Congo hemorrhagic fever virus (CCHFV) and Rift Valley fever virus (RVFV).1 The frequent report of novel bunyaviruses, detected in humans, animals, and plants together with the high genetic diversity among its species, led to a reclassification by the International Committee on Taxonomy of Viruses.2 This illustrates the ubiquity, the variety of hosts, and the epidemic potential of viruses in the Bunyavirusae order, which is now a collection of nine viral families, comprising 13 genera (Figure S1).

The scope of this review includes the four genera that have been associated with human disease, ie, Orthohantaviruses, Orthobunyaviruses, Phleboviruses, and Nairoviruses (Figure 1).

Many of these viruses need to be handled in biosafety level (BSL)-3 or -4 laboratories, which complicates the research. Yet, it is important to step up to the challenge since these emerging human viruses are now spread over more than 80 countries in Europe, Asia, Middle East, America, and Africa.3 The great diversity and continuous emergence of new bunyaviral species that cause severe disease make it unfeasible to develop drugs or vaccines for every single virus.

List of abbreviations: AKAV, Akabane orthobunyaviruses; ANDV, Andes virus; BMP, bismonoacylglycerol-phosphate; BSL, biosafety level; BUNV, Bunyamwera virus; CCHFV, Crimean-Congo hemorrhagic fever virus; cRNA, complementary RNA; DC-SIGN, dendritic cell-specific ICAM-grabbing nonintegrin; eIF4F, eukaryotic initiation factor 4F; EREV, Erve virus; HAZV, Hazara virus; HPS, hantavirus pulmonary syndrome; IFNAR1, Lack of alpha/beta interferon receptor; IMPDH, inosine monophosphate dehydrogenase enzyme; IRF-3, IFN regulatory factor-3; KUPV, Kupe virus; LACV, La Crosse virus; LASV, Lassa virus; LEAV, Leanyer virus; L-segment, large segment; MPRLV, Maporal virus; M-segment, middle-sized segment; N-protein, nucleoprotein; P bodies, processing bodies; PTV, Punta Toro virus; PUUV, Puuma virus; RdRp, RNA-dependent RNA polymerase; RVFV, Rift Valley fever virus; SBV, Schmallenberg virus; SFTSV, severe fever with thrombocytopenia syndrome virus; SNV, Sin Nombre virus; S-segment, small segment; UUKV, Uukuniemi virus; vRNA, viral RNA
Therefore, comprehensive efforts towards the development of antivi-
ral drugs with an extended efficacy against an entire virus family or
even virus order need to be made. These offer protection against
not only the (re)emerging viruses of today but also from the pandemic
threats of tomorrow. To aid in such efforts, we here review the avail-
able knowledge of potential druggable targets in the replication cycle
of these viruses together with current available tools and models.

2 | PARTICLE STRUCTURE AND VIRAL
PROTEINS

2.1 | Virion and genome

Bunyaviruses have spherical 80- to 120-nm-sized enveloped virions. Their lipid bilayer envelop is covered with capsomers consisting of transmembrane glycoproteins (Gc and Gn). The genome exists out of negative sense single-stranded \([(-)ss]RNA\), which is trisegmented in all human pathogenic genera. These RNA segments, together with oligomers of N-proteins, form looped RNP. A single L-protein is bound to each of the RNA segments (Figure 2).

The large segment (L segment) encodes the RNA-dependent RNA polymerase (RdRp), or L-protein, which is responsible for the production of complementary RNA (cRNA) and viral RNA (vRNA). The middle-sized segment (M segment) encodes for the Gc and Gn glycoproteins. Depending on the species, the M segment also codes for the NSm protein. The small segment (S segment) contains the transcript for the nucleoprotein (N-protein), which, like all above-
mentioned proteins, is encoded in the (−)-sense. The S segment further codes for the nonstructural protein NSs in either negative or positive orientation (as in phleboviruses and orthobunyaviruses, respectively) but can also be lacking (as is the case in some orthohantaviruses.4,5

2.2 | L-protein

The L-protein is responsible for transcription of the (−)-ssRNA and replication of new vRNA. Both these processes occur in the cytosol where newly translated L-proteins can interact with either additional L-proteins to facilitate replication or with newly synthesized vRNA to be assembled into new viral particles.5 While the size of the L-proteins may vary between families, three subdomains, ie, the finger, palm, and thumb can be distinguished in all L-proteins. The relative orientation of these three subdomains defines the catalytic cavity, which can be attuned to facilitate different stages of replication.6 All L-proteins recognize highly conserved complementary 3′ and 5′ extremities of the genome segments that either form a double stranded “pan-handle” bound by the L-protein or both ends are bound separately to the L-protein.7,8 These 5′ and 3′ UTR are acting as promoter and transcription termination signal for the viral polymerase.9,10 Similar regions were found in influenza viruses, where they also contribute to the activation of several polymerase functions.11

The endonuclease and RdRp domains of the L-protein are present throughout the bunyaviruses and share functional characteristics and structural similarities with other (−)-stranded segmented viruses such as arenaviruses and orthomyxoviruses (Figure 3A).12

The endonuclease domain is responsible for cap snatching, which initiates transcription in all orthomyxoviruses, arenaviruses, and bunyaviruses. The endonuclease cleaves the 5′-end of host mRNAs to acquire primers for viral mRNA transcription. The manganese-dependent endonuclease domain of bunyaviruses is located at the N-terminus of the L-protein, with exception of the nairoviruses where it is located more downstream (Figure 3A).13,14 The aa similarity of the endonuclease domain of species within the four studied bunyaviral families is 50% to 80% conserved, whereas between families, this is 30% to 45%. The degree of similarity with the arena and influenza

![Figure 3](https://example.com/fig3.png)

**FIGURE 3** A. Comparison of L-proteins of segmented (−)-ssRNA viruses. The proteins are represented as bars and domains of interest are the endonuclease domain (in blue) and polymerase domain (in yellow). Numbers above the bars indicate the area of the region that has been used in the comparison. B. Heatmaps of the amino acid similarity of endonuclease domains (left) and polymerase domains (right) between (−)-ssRNA viruses. Rift Valley fever virus (RVFV), Bunyamwera virus (BUNV), Hantaan virus (HNTV), Crimean-Congo hemorrhagic fever virus (CCHFV), severe fever with thrombocytopenia syndrome virus (SFTSV)
domains is 28% to 45% and 22% to 38%, respectively (Figures 3B and S2). However, within the active site of these domains, there are motifs that are highly conserved (H.E/D..PD..E/D). Their crucial function and conserved regions makes such domains a suitable target for antiviral endeavors. Successes have already been achieved against the endonuclease of influenza, confirming this enzyme is indeed a druggable target.\textsuperscript{15} Such compounds include endonuclease inhibitors pimodivir/JNJ872 (formally VX-787), which is active against a diverse panel of influenza A virus strains and influenza JNJ5806 (formally AL-794) (J&J/Alios) and S-033188 (Shionogi).\textsuperscript{17} This not only shows that the endonuclease is a viable drug target but its conservation among strains and species may also indicate possibilities for the development of pan-bunya inhibitors. However, it is not self-evident that such compounds will be equipotent against all bunyaviruses, since subtle differences remain.

A second highly conserved domain among (-)ssRNA viruses is the active RdRp domain in the central region of the L-proteins of bunyaviruses and arenaviruses and in the PB1 subunit of orthomyxoviruses. While the aa similarity of this region between bunyavirus families is below 50% (Figures 3B and S2), there are highly conserved motifs (preA/F..A..B..C..D..E..H) that extend into arenaviruses and influenza viruses.\textsuperscript{5} This could make it a target for broad-acting antivirals. In fact, some polymerase-targeting broad-acting antiviral drugs have been reported. Galidesivir (BCX4430, BioCryst Pharmaceuticals) is an adenosine nucleoside RdRp-inhibitor currently being developed against filoviruses (e.g., Ebola virus and Marburg virus), also exerts activity against coronaviruses, picornaviruses, paramyxoviruses, flaviviruses, orthomyxoviruses, arenaviruses, and bunyaviruses.\textsuperscript{18} GS-5734, a monophosphoramidate prodrug of an adenosine analogue, is being developed as anti-filovirus drug. Its acting range includes also flaviviruses and paramyxoviruses, but not bunyaviruses or arenaviruses.\textsuperscript{19} Also favipiravir/T-705 exerts a wide range of anti-RNA-virus inhibition, including some minor activity against bunyaviruses.\textsuperscript{20} The antiviral activity of favipiravir is discussed in more detail in Section 4. The similarities between the polymerases of bunyaviruses, arenaviruses, and influenza viruses, ie, their common motifs and similar architecture, could point in the direction of a common ancestor.\textsuperscript{6} From an antiviral prospective, this could be a very interesting notion, since a single drug might be able to target them all.

### 2.3 | N-protein

The N-protein is a variable and multifunctional entity of all bunyaviruses (Figure 4). Their main function, the encapsulation of
vRNA and cRNA, is conserved throughout all (-)ssRNA viruses. They do so by forming ribonucleoprotein complexes, thereby protecting the viral genomic material against host defense mechanisms. Structural analysis shows that there is limited overall aa similarity among N-proteins, both between viral families and genera, but also between bunyaviruses and the other (-)ssRNA viruses.

The Bunyamwera virus (BUNV) N- and C-terminal aa’s protrude outward from the protein core domain and are able to interact with neighboring N-proteins, causing head-to-tail interactions.21 This way, these proteins can form ring-shaped tetramers. This multimerization might be a flexible feature though, since it was observed that Schmallenberg virus (SBV) N-proteins form both tetrameric and hexameric multimers.22 N-N-protein interactions were also found in BUNV and Leanyer virus (LEAV), suggesting this is at least a genus-wide conserved feature.23,24 The structure of LEAV shows two distinct domains together forming the core domain: an N-lobe and C-lobe (Figure 5A). Between these two lobes, a positively charged cleft is formed that can hold 11 nt of ssRNA, which together form filamentous RNPs. The ssRNA is bound to the LEAV N-protein through hydrogen bonds to the backbone and maybe also to the bases. On the surface of the N-protein, there is a hydrophobic region that is suggested to be involved in N-N-protein interactions.24

![A](viral_n-proteins.jpg)

**FIGURE 5** Comparison of N-proteins of segmented (-)ssRNA viruses. A, Domain distribution comparison between bunyaviruses. The proteins are represented as bars. B, Heatmap of the amino acid similarity of N-proteins between (-)ssRNA viruses. Leanyer virus (LEAV), Rift Valley fever virus (RVFV), Hantaan virus (HNTV), Crimean-Congo hemorrhagic fever virus (CCHFV), severe fever with thrombocytopenia syndrome virus (SFTSV)
The typical two lobed structure of N-proteins was also observed in phleboviruses, but no protruding C-terminal arm observed. These rather appear to be folded back against the protein.\textsuperscript{25} Just as in orthobunyaviruses, a strong hydrophobic region was found, which allows interaction with other N-proteins.\textsuperscript{26} Even in the sequence dissimilar Uukuniemi virus (UUKV), such N-N interactions have been observed.\textsuperscript{27} The hydrophobic region is highly conserved among phleboviruses and is found in a pocket at the N-lobe surface. This allows the typical ring-shaped oligomers to form, but these show variability in size and shape. This indicates structural flexibility of N-protein complexes in combination with RNA. The ring shape was also seen in TOSV N-protein oligomers, but on introducing RNA to such oligomers, a helical RNP was observed.\textsuperscript{28} The binding of RNA in this ring- or helical-shaped manner allows it to be concealed. Binding of RNA occurs at the interface of the N-protein N- and C-lobe where a cleft is formed containing a positively charged patch that allows, in case of RVFV, the binding of six RNA bases. Such a hydrophobic patch is conserved among phleboviruses.\textsuperscript{25}

While the N-protein of hantaviruses has almost twice the molecular weight as the same protein in orthobunyaviruses and phleboviruses, similar structural properties are observed. There are the N- and C- terminal arms and subsequent binding pockets that together regulate N-N-protein interactions, and there is the hydrophobic cleft at the interface of the N- and C-lobes to accommodate RNA.\textsuperscript{29} On top of these similarities, there are some additional functionalities attributed to hantaviral N-proteins. It has been demonstrated that trimers of the protein can substitute the eukaryotic initiation factor 4F (eIF4F) cap-binding complex, which is responsible for translation initiation. By taking over the helicase function of eIF4A subunits, binding to initiation complexes like eIF4G and binding to 5′ m7G caps just like eIF4E, it makes eIF4F obsolete.\textsuperscript{30} The N-protein facilitates the association of ribosomal protein S19 and the viral mRNA 5′ UTR allowing ribosomes to be loaded onto the mRNA.\textsuperscript{21} Furthermore, N-proteins are able to interfere with cellular mRNA decay by associating with processing bodies (P bodies), which are hot spots for cap snatching.\textsuperscript{32} Besides these translational-enhancing properties, the hantavirus N-protein has also been found to interfere in host innate immune responses.\textsuperscript{33}

Nairovirus N-proteins do not share the common N- and C-lobe structure described above. Their N-proteins have a racket shape that consists of a globular (or head) domain and a stalk domain.\textsuperscript{34,25} The globular domain is structurally very similar to the Lassa virus (LASV) N-protein N-terminal domain, but despite the similarity, they may not have equivalent functions, since the CCHFV N-protein lacks the 3′-5′ exoribonuclease functionality attributed to the LASV N-protein.\textsuperscript{35,36} The stalk domain can alter its relative position, thereby altering the function of the protein. One main function is again the binding of RNA, which seems to drastically modify its structure, and the interaction with the globular domain of neighboring N-proteins and thereby form circular oligomers.\textsuperscript{37} Three positively charged regions (two on the globular domain, one on the stalk) are present and may play a role in RNA binding, which is in contrast to other bunyaviral families with their clear RNA-binding cleft.

However, the RNA-binding domains overlap with other functional sites; thus, it seems likely that in an RNA-bound state, the other abilities are inhibited.\textsuperscript{27} It was shown that CCHFV N-protein allows cap-independent translation of viral RNA by interacting with eIF4G, but details about these interactions are lacking.\textsuperscript{38} The structure of the N-protein of CCHFV seems to be shared by all nairoviruses, since structures of HAZV, Kule virus (KUPV), and Erve virus (EREV) showed very similar structures, although functionality might slightly vary.\textsuperscript{39}

Our own aa similarity comparison of the N-proteins shows there is very limited similarity between viral families; this is substantial within families (Figure 5B) (Supporting Information). Within hantaviruses, the sequence is especially conserved, from 62% up to 78%. We observed that UUKV N-protein shares lower sequence similarity with other phleboviruses. Lower aa identity of UUKV was reported earlier.\textsuperscript{26} Whereas the similarity between families is low, their structural and functional comparability seems, with exception of nairoviruses, much higher. The numerous sites for interaction of the N-protein with other viral proteins, RNA, and host factors, together with their crucial functions in the viral replication cycle, could possibly make good antiviral targets.\textsuperscript{40} This is supported by findings of small molecule targeting N-proteins in other (-)ssRNA viruses. Inhibitors against conserved epitopes of the N-protein of influenza (eg, nucleozin) and RSV (eg, RSV604 and AstraZeneca) have been discovered.\textsuperscript{41,42} Antiviral effect against influenza was observed by targeting N-protein with the nonsteroidal antiinflammatory drug naproxen. It binds the highly conserved RNA binding groove of the N-protein, demonstrating that this is indeed a druggable target and thus could also be a potential target in bunyaviruses.\textsuperscript{43}

2.4 | Glycoproteins

The viral envelope is covered by oligomers of membrane glycoproteins (Gn and Gc), which are derived through endoproteolytic cleavage of the RNA M segment-encoded polyprotein.\textsuperscript{44} In CCHFV, this polyprotein is cotranslationally cleaved into the PreGn and PreGc precursors, which are then cleaved by SKI-1 and SK1-1-like proteases to generate the N-termini of Gn and Gc, respectively.\textsuperscript{45} The outward-directed domains are variable between families and species and are responsible for the attachment to host cell. This variability is reflected in the wide range of host cell receptors that have been described (see Section 3) and could make it difficult to use these domains as a target for broad-acting antivirals. Moreover, viruses have shown that they can easily mutate their receptor-binding interface to escape the drug pressure and pay little to no cost in fitness to do so. This would quickly lead to the emergence of drug resistant variants, thus rendering antivirals targeting these domains ineffective. The domain that is directed inwards into the virion is able to do so. This would quickly lead to the emergence of drug resistant variants, thus rendering antivirals targeting these domains ineffective. The domain that is directed inwards into the virion is able to interact with the N-proteins of the RNP or directly with the RNA.\textsuperscript{46,47} The disruption of these critical interactions could interfere with the viral replication cycle, making them potentially good antiviral targets.
2.5 | Nonstructural proteins

Bunyaviruses use their nonstructural proteins in strategies to interact with apoptotic pathways and to interfere with the host innate immune system. Unlike the structural proteins, these proteins are not conserved throughout the viral order. The nonstructural proteins can be lacking entirely, such is the case in most hantaviruses. The NSs (encoded on the S segment) and NSm (encoded on the M segment) can both be encoded in the (−)sense as in orthobunyaviruses, or the NSs can be encoded in the (+)sense, as is the case for the phenuiviruses.

2.6 | NSs protein

The main purpose of the NSs protein is to interfere with the host IFN-mediated immunity; it therefore is a major virulent factor. The NSs of phleboviruses and orthobunyaviruses is transported to the nucleus of infected cells and prevents the transcription of IFN by suppressing IFN regulatory factor-3 (IRF-3). The NSs of RVFV induces a characteristic filamentation in infected cell nuclei. The structure of an RVFV NSs protein was reported, showing a stable core domain that might contain all essential determinants for nuclear translocation and filamentation. While this core domain has only a 15% to 30% sequence identity between phleboviruses, these all have a similar core and filament formation. While this core domain has only a 15% to 30% sequence identity between phleboviruses, these all have a similar core and filament formation. While this core domain has only a 15% to 30% sequence identity between phleboviruses, these all have a similar core and filament formation.

3 | REPLICATION CYCLE

3.1 | Viral attachment and entry

The replication cycle of the Bunyavirales is in general very similar among its members (Figure 6). Bunyaviruses may, depending on the family, viral species, or type of host cell, use different cellular targets for attachment and employ different host entry pathways. For the Phenuiviridae family and a variety of bunyaviruses, the most widely described attachment factor is dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN). Mutations or knock down of these molecules result in lower infection rates in vitro.57-59 A second attachment factor in these viruses is L-SIGN, another human C-type lectin, which shares a 77% aa sequence homology to DC-SIGN.60 Even though these factors have not been extensively studied in other bunyaviruses, they are involved in the infection pathway of other viruses such as dengue, Lassa, and hepatitis C virus.61-63 It was recently shown that heparan sulfate proteoglycan is also an important attachment factor for the SBV and Akabene orthobunyaviruses (AKAV).64 Hantaviruses use integrin as receptor for cell entry; β1 integrin by nonpathogenic hantaviruses and β3 integrin by the pathogenic species in vitro.65 Cell entry varies between bunyaviruses, with clathrin-mediated, calveolin-mediated, and independent endocytosis all being described in one or more bunyaviruses, depending also on the host cell type.66-67

Envelope fusion with the endosomal membrane is thought to be triggered by the acidification of the late endosome, which initiate a conformational change of the viral particle glycoproteins. However, it was recently shown that also potassium channels play a crucial role in this step and thus could be potential druggable targets.58-60-61 In UUKV, this is promoted by the presence of the late endosomal phospholipid bis(monoacylglycero)-phosphate (BMP).62 Essential histidine residues have been identified in the RVFV Gc-protein by mutational analysis, which serve as sensors for acidification in endosomal lumen and often define the optimal pH value for virus fusion.73-74 Hantaviruses depend heavily on cholesterol for membrane fusion.75 The Puumala virus (PUUV) Gc has shown to be the membrane fusion effector, and it presents a class II membrane fusion protein fold in its postfusion conformation.76-77 Such a fold was also observed in RVFV.78

3.2 | Transcription and translation of bunyaviral proteins and genome replication

The L-protein becomes active once it is released in the cytosol and starts by transcribing the three segments of the (−)sense genome. This process is preceded by cap snatching, where a fragment of 12- to 18-nt-long 5′-capped primer is stolen from host cell mRNA to initiate the synthesis of viral mRNA's, which will be translated into new viral proteins.79 Translation of the L-, N-, and NS proteins occurs in the cytosol by free ribosomes, while the viral glycoproteins are produced by the ER-membrane bound ribosomes.80 For the replication of the genome, cRNA, i.e. a (+)sense copy of the genome segments, is created by de
novo synthesis, which is suggested to be initiated by an interaction between two L-proteins. If this is indeed the case, targeting this critical interaction could be an efficient way to inhibit bunyavirus replication.

3.3 | Assembly and exocytosis

The newly formed glycoproteins instantly form oligomers in the ER membrane. From there, they target to the Golgi to assemble, allowing the new viral particles to bud from the Golgi membrane, which is a unique feature for the bunyaviruses since all other (−)ssRNA viruses bud from the cellular membrane. This mechanism was targeted in RVFV by a small molecule, G202-0362, which seems to inhibit assembly and/or exocytosis by depolymerizing microtubules.

In the replication complexes, the glycoprotein cytoplasmic tails, which are located on the inside of the virion after budding, are presented outwards towards the cytosol. This could be the bunyavirus alternative to matrix proteins, since the tail domain of the glycoproteins is able to interact with the RNP and initiate assembly of new viral particles. The assembly of RVFV is induced by an interaction between the RNP N-proteins and the viral glycoproteins. This seems to be a nonselective process that results in particles carrying a random amount of genomic segments. It is not evident that this mechanism is the same for all bunyaviruses. In CCHFV, the Gn cytosolic tail directly binds to the RNA to initiate assembly. This could enable a more specific selection of genomic segments. Besides, it was shown that assembly mechanisms depend not only on the virus species but also on the type of cell that is infected.

3.4 | Available model systems and tools for antiviral research

Since numerous bunyavirus species require BSL-3 and 4 facilities for handling, only a relatively limited number of research facilities are equipped to study these viruses.

3.5 | Biosafety and surrogate models

Working with a surrogate virus may be a better option. For several highly pathogenic bunyaviruses, such surrogates are described. The Hazara virus (HAZV) is a CCHFV-related orthonairovirus that is nonpathogenic to humans and can therefore be used both in in vitro assays to study the effect of antiviral agents and in mouse models at BSL-2. A closer
alternative would be the CCHFV AP92 or AP92-like strains, which have a moderately reduced virulence compared with the wild-type virus. However, a first lethal case has been reported. This, together with the lack of a detailed virulence and safety studies, makes that in most countries this is still classified as a BSL-4 pathogen. Unlike wild-type CCHFV, there are no reverse genetics systems available for Hazara or AP92.

For RVFV (a BSL-3 pathogen), the attenuated MP-12 strain (BSL-2) may be a suitable surrogate. MP-12 is a cell-culture–attenuated strain derived from the RVFV ZH548 strain. It replicates robustly in vitro and in vivo, making it a suitable research tool (Table 1). All orthohantaviruses are classified as either BSL-3 or -4 pathogens. The Maporal virus (MPRLV), a New World hantavirus, has been proposed as a potential surrogate, since there is currently no evidence that it can infect humans or cause disease.

Most orthobunyaviruses are BSL-2 pathogens, because symptoms in humans are mostly limited to fever, headache, joint and muscle aches, nausea, and rash. Many models and tools are available to study these viruses (Table 1).

Not all highly pathogenic bunyaviruses can currently be studied by using surrogates. For example, for severe fever with thrombocytopenia syndrome virus (SFTSV) (BSL-3), there are currently no attenuated strains or surrogates available.

The majority of bunyaviruses replicate in a wide variety of routinely used cell-culture systems, allowing to study their replication cycle (and inhibition thereof) in cell-based assays. The most widely used cell lines are Vero, AS49, and BHK-21 (Table 1).

3.6 Animal infection models

While many bunyaviruses are not (or only low) pathogenic in immunocompetent rodents, RVFV is highly pathogenic in immunocompetent mice and hamsters. The virulent RVFV-ZH548 strain is pathogenic in wild type mouse models, whereas the attenuated MP-12 strain only gives similar pathogenicity in mice that lack the alpha/beta interferon receptor (IFNAR-−) and STAT-1 KO mice. This indicates that the virulent strain possesses viral factors to interfere with IFN-mediated innate immune response.

IFNAR-−/− mice are also highly sensitive to CCHFV, and HAZV in which infection causes acute hepatitis and death of the animals within a few days after infection. CCHFV infection is robust in STAT-1 KO mice too. An alternative rodent model are Golden Syrian hamsters, which are susceptible to RVFV and Hantaviruses. When devoid of functional STAT-2, they are also highly susceptible to SFTSV, showing thrombocytopenia, typical marked systemic inflammation, and mortality.

Hamsters develop a lethal Hantavirus pulmonary syndrome (HPS)-like disease when infected with ANDV, while infection with the Sin Nombre virus (SNV) results in an asymptomatic infection. MPRLV, which does not cause disease in humans, causes partial lethality and HPS-like disease in these hamsters. This makes the Syrian hamster model currently the best Hantavirus infection and HPS-disease model, making it well suited to study the antiviral efficacy of small molecule inhibitors.

4 CURRENTLY USED ANTIVIRAL COMPOUNDS IN BUNYAVIRAL INFECTIONS

4.1 Ribavirin

Ribavirin is a purine nucleotide analog approved for the treatment of RSV and Lassa virus and was until 2014 routinely used for the treatment of infections with hepatitis C virus. In vitro antiviral activity against CCHFV has been reported, and the compound was shown to reduce CCHFV viral load and to slow down disease progression in an IFNAR-−/− mouse infection model. Its antiviral effect derives from multiple mechanisms of action. The foremost antiviral mechanism against RNA viruses (described for flaviviruses and paramyxoviruses) is thought to be the inhibition of the inosine monophosphate dehydrogenase enzyme (IMPDH), resulting in the depletion of GTP pools.

Ribavirin is currently the only drug used in a clinical setting against CCHFV infection in humans. Clinical benefits have been controversial, since randomized placebo-controlled clinical trials are not in line with the Declaration of Helsinki. However, available studies indicate that ribavirin is effective during initial viremia when disease is still mild or moderate, but not once patients reach the hemorrhagic stage. Consequently, ribavirin could also be used as a (postexposure) prophylaxis for health care workers at risk of contracting CCHFV. The blocking of the viral replication by ribavirin could explain why the drug is beneficial during the viremic phase and not in the later hemorrhagic phase, which is the result of released proinflammatory cytokines and the disruption of coagulation cascades. Currently, two phase II trials have been enrolled to get more insight in the safety and efficacy of ribavirin (NCT00992693 & NCT02483260).

Ribavirin has also been used occasionally in the treatment of HPS in humans, but due to the small numbers of studies, no defining conclusions can be drawn. However, a significant reduction in mortality in rodents has been observed.

4.2 Favipiravir

Favipiravir acts as a nucleobase analog that functions in its active form as a substrate by the RdRp and inhibits the RNA polymerase activity. It was first described as antiviral drug against influenza, but in vitro and in vivo activity has also been demonstrated against a variety of other RNA viruses, such as arenaviruses, filoviruses, togaviruses, and bunyaviruses. In case of bunyaviruses, its in vitro activity is superior to ribavirin. Its ability to increase survival rates in PTV- and RVFV-infected hamsters and in SFTSV- and CCHFV-infected mice further proof the potency of favipiravir.

Favipiravir has been approved in Japan for the use in patients infected with novel or reemerging influenza viruses. The drug has also been suggested for the treatment of Ebola infections, and clinical trials have been performed despite concerns of teratogenicity shown in animals. These trials showed favipiravir to be well tolerated and decrease the mortality of patients with the low viral load. Promising data obtained in preclinical experiments, together with positive
| Genus            | Virus          | BSL | Vector Transmission                  | In Vitro Systems | Reverse Genetics System | Animal Models                           | Ref               |
|------------------|----------------|-----|--------------------------------------|------------------|-------------------------|-----------------------------------------|-------------------|
| Orthohantavirus  | Andes virus    | 3   | Inhalation aerosolized excrement long-tailed pigmy rice rat (Oligoryzomys fulvescens) / human-to-human transmission | Vero             | Minireplicon system     | Syrian hamster                          | 100,112,118-120   |
|                  | Hantaan virus  | 3   | Inhalation aerosolized excrement striped field mouse (Apodemus agrarius) | Vero             | Minireplicon system     | C57BL/6 mice, BALB/c mice, Syrian hamster | 121-123           |
|                  | Puumala virus  | 3   | Inhalation aerosolized excrement bank vole (Myodes glareolus) | Vero             | -                       | Syrian hamster                          | 124,125           |
|                  | Sin Nombre virus | 3 | Inhalation aerosolized excrement deer mouse (Peromyscus maniculatus) | Vero, HUVEC      | -                       | Immunosuppressed Syrian hamsters         | 120,126,127       |
| Orthonairovirus   | CCHFV          | 4   | Tick (Hyalomma spp.) / contact with infectious blood or body fluids | Vero, SW-13, Huh-7 | Minireplicon system VLP system | 129S6/SvEv STAT-1−/− mice, IFNAR−/− mice | 97,104,128,129    |
|                  | Dugbe virus    | 3   | Tick (Amblyomma variegatum) | BHK              | -                       |                                        | 130               |
|                  | Hazara virus   | 2   | Ticks (Ixodes) | Vero, A549, SW-13 | -                       | IFNAR−/− mice                           | 88,131            |
| Phlebovirus       | RVFV           | 3   | Mosquito (mainly Aedes and Culex) / contact with infectious blood or body fluids | Vero, A549, Hek293 | Minireplicon system VLP system | IFNAR−/− mice, Syrian hamsters | 91,92,98,132-134  |
|                  | Punta Toro virus | 2 | Sandfly (Phlebotominae) | Vero, LLC-MK2, Hek293 | -                       | C57BL/6 mice, Syrian hamsters | 135-137           |
|                  | SFTSV          | 3   | Tick (Haemaphysalis longicornis) / contact with infectious blood or body fluids | DH82, Vero, Huh-7 | Minireplicon system     | C57BL/6 mice, IFNAR−/− mice             | 138-141           |
| Toscana virus     | 2   | Sandfly (Phlebotominae) | Vero, HeLa, Hek293T | Minireplicon system | BALB/c mice | 142,143                                |
|                  | Uukuniemi virus | 2 | Tick (Ixodes ricinus) | BHK, A549        | Minireplicon system     |                                         | 144-147           |
| Orthobunyavirus   | Bunyamwera virus | 2 | Mosquito (mainly Aedes) | Vero, BHK, A549  | Minireplicon system     | Swiss albino suckling mice, 129S6/SvEv mice | 148-150           |
|                  | La Crosse virus | 2   | Mosquito (mainly Aedes) | Vero, RAW264-7   | Minireplicon system     | C57BL/6 mice, Swiss albino suckling mice | 151,152           |
|                  | Oropouche virus | 3 | Mosquito (mainly Aedes and Culex) | Vero, A549 | Minireplicon system VLP system | Swiss albino suckling mice, Syrian hamster | 153-157           |

Abbreviations: BHK, baby hamster kidney; CCHFV, Crimean-Congo hemorrhagic fever virus; Hek293, human embryonic kidney 293; HUH-7, human hepatoma-7; HUVEC, human umbilical vein endothelial cells; IFNAR, interferon α/β receptor; LLC-MK2, Lilly Laboratories Cell–Monkey Kidney 2; RVFV, Rift Valley fever virus; SFTSV, Severe fever with thrombocytopenia syndrome virus; STAT-1, signal transducer and activator of transcription 1; VLP, virus-like particle.
results from clinical trials against other RNA viruses resulted in clinical trials with favipiravir against SFTSV (UMIN000022398 & UMIN000029020), leading to a phase three clinical trial (JapicCTI-183872).117

4.3 | Perspectives

The order of the Bunyavirales with its nine viral families, various animal hosts, and wide range of transmission vectors have a major impact and form a severe threat to human health. There are no drugs for the prevention or treatment of bunyavirus infections, and current response to bunya-related disease is still largely insufficient. Even though bunyaviruses prove a tremendous challenge to the field of antiviral research, it is imperative to step up to the challenge. Anti-viral therapy has progressed enormously in the last decades, and history has taught us that it is possible to achieve what was sometimes deemed impossible (e.g., one pill a-day treatment regimen for HIV and a cure for a chronic HCV infection after only 12 wk of treatment). Thus, if sufficient effort is put forward by the scientific community, insight into bunyavirus biology is gained and new small molecule inhibitors will be identified that can potentially be developed as antiviral treatment. This holds truth even against a viral order as diverse as the Bunyavirales. The current paper provides an in-depth review of the biology of bunyavirus replication, and we expand on how certain viral proteins can be exploited for antiviral drug development, together with the level of conservation of their biological functions, structure, and genetic similarity.

ROLE OF THE FUNDING SOURCE

The Infect-ERA grant “ESCential” supported this work but had no involvement in any aspect of the content. The corresponding author had full access to all the data and had final responsibility in the decision to submit for publication.

ACKNOWLEDGEMENTS

This work was kindly supported by the Infect-ERA grant “ESCential.” We thank Jelle Matthijnssens for his collaboration and Piet Maes for managing our servers.

CONFLICT OF INTEREST

The authors have no competing interest.

ORCID

Sebastiaan ter Horst  
https://orcid.org/0000-0001-7981-6376
Nádia Conceição-Neto  
https://orcid.org/0000-0002-9659-6835
Johan Neyts  
https://orcid.org/0000-0002-0033-7514
Joana Rocha-Pereira  
https://orcid.org/0000-0001-8299-3787

REFERENCES

1. World Health Organization, www.who.int. 2018 Annual review of diseases prioritized under the Research and Development Blueprint. Geneva, Switzerland: World Health Organization 2018.

2. Adams MJ, Lefkowitz EJ, King AMQ, et al. Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2017). Arch Virol. 2017;162(8):2505-2538.

3. Berger S. Bunyaviridae infections—misc. In: Miscellaneous Bunyaviridae: Global Status. 2017 edition ed. Los Angeles, California: Gideon Informatics, Inc; 2017:7-11.

4. Walter CT, Barr JN. Recent advances in the molecular and cellular biology of bunyaviruses. J Gen Virol. 2011;92(Pt 11):2467-2484.

5. Ferron F, Weber F, de la Torre JC, Reguera J. Transcription and replication mechanisms of Bunyaviridae and Arenaviridae L proteins. Virus Res. 2017;234:118-134.

6. Gerlach P, Malet H, Cusack S, Reguera J. Structural insights into bunyavirus replication and its regulation by the vRNA promoter. Cell. 2015;161(6):1267-1279.

7. Barr JN, Wertz GW. Bunyamwera bunyavirus RNA synthesis requires cooperation of 3′- and 5′-terminal sequences. J Virol. 2004;78(3):1129-1138.

8. Kolakofsky D. dsRNA-ended genomes in orthobunyavirus particles and infected cells. Virology. 2016;489:192-193.

9. Barr JN, Rodgers JW, Wertz GW. The Bunyamwera virus mRNA transcription signal resides within both the 3′ and the 5′ terminal regions and allows ambisense transcription from a model RNA segment. J Virol. 2005;79(19):12602-12607.

10. Barr JN, Rodgers JW, Wertz GW. Identification of the Bunyamwera bunyavirus transcription termination signal. J Gen Virol. 2006;87(1 Pt 1):189-198.

11. te Velthuis AJ, Turrell L, Vreede FT, Fodor E. Uncoupling influenza A virus transcription and replication through mutation of the unpaired adenosine in the viral RNA promoter. J Virol. 2013;87(18):10381-10384.

12. Das K, Arnold E. Negative-strand RNA virus L proteins: one machine, many activities. Cell. 2015;162(2):239-241.

13. Reguera J, Weber F, Cusack S. Bunyaviridae RNA polymerases (L-protein) have an N-terminal, influenza-like endonuclease domain, essential for viral cap-dependent transcription. PLoS Pathog. 2010;6(9):e1001101.

14. Holm T, Kopicki JD, Busch C, et al. Biochemical and structural studies reveal differences and commonalities among cap-snatching endonucleases from segmented negative-strand RNA viruses. J Biol Chem. 2018;293(51):19686-19698.

15. Reguera J, Gerlach P, Rosenthal M, et al. Comparative structural and functional analysis of bunyavirus and arenavirus cap-snatching endonucleases. PLoS Pathog. 2016;12(6):e1005636.

16. Zhou Z, Liu T, Zhang J, Zhan P, Liu X. Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. Drug Discov Today. 2018;23(3):503-518.

17. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late-phase clinical trial. Influenza Other Respi Viruses. 2017;11(3):240-246.

18. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature. 2014;508(7519):402-405.

19. Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Rep. 2017;7(1):43395.

20. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smeep DF, Barnard DL. Favipirvir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100(2):446-454.
21. Leonard VH, Kohl A, Osborne JC, McLees A, Elliott RM. Homotypic interaction of Bunyamwera virus nucleocapsid protein. J Virol. 2005;79(20):13166-13172.

22. Dong H, Li P, Elliott RM, Dong C. Structure of Schmallenberg orthobunyavirus nucleoprotein suggests a novel mechanism of genome encapsidation. J Virol. 2013;87(10):5593-5601.

23. Eifan SA, Elliott RM. Mutational analysis of the Bunyamwera orthobunyavirus nucleocapsid protein gene. J Virol. 2009;83(21):11307-11317.

24. Niu F, Shaw N, Wang YE, et al. Structure of the Leanyer orthobunyavirus nucleoprotein-RNA complex reveals unique architecture for RNA encapsidation. Proc Natl Acad Sci U S A. 2013;110(22):9054-9059.

25. Ferron F, Li Z, Danek EI, et al. The hexamer structure of Rift Valley fever virus nucleoprotein suggests a mechanism for its assembly into ribonucleoprotein complexes. PLoS Pathog. 2011;7(5):e1002030.

26. Raymond DD, Piper ME, Gerrard SR, Smith JL. Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc Natl Acad Sci U S A. 2010;107(26):11769-11774.

27. Katz A, Freilberg AN, Backstrom V, et al. Oligomerization of Uukuniemi virus nucleocapsid protein. Virol J. 2010;7(1):187.

28. Olal D, Dick A, Woods VL Jr, et al. Structural insights into RNA encapsidation and helical assembly of the Toscana virus nucleoprotein. Nucleic Acids Res. 2014;42(9):6025-6037.

29. Olal D, Daumke O. Structure of the hantavirus nucleoprotein provides insights into the mechanism of RNA encapsidation. Cell Rep. 2016;14(9):2092-2099.

30. Mir MA, Panganiban AT. A protein that replaces the entire cellular eIF4F complex. EMBO J. 2008;27(23):3129-3139.

31. Haque A, Mir MA. Interaction of hantavirus nucleocapsid protein with ribosomal protein S19. Virol J. 2010;84(23):12450-12453.

32. Mir MA, Duran WA, Hjelle BL, Ye C, Panganiban AT. Storage of cellular X’ mRNA caps in P bodies for viral cap-snatching. Proc Natl Acad Sci U S A. 2008;105(49):19294-19299.

33. Taylor SL, Krempel RL, Schmaljohn CS. Inhibition of TNF-α-induced activation of NF-κB by hantavirus nucleocapsid proteins. Ann N Y Acad Sci. 2009;1171(Suppl 1):E86-E93.

34. Carter SD, Surtees R, Walter CT, et al. Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J Virol. 2012;86(20):10914-10923.

35. Guo Y, Wang W, Ji W, et al. Crimean-Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyaviruses. Proc Natl Acad Sci U S A. 2012;109(13):5046-5051.

36. Qi X, Lan S, Wang W, et al. Cap binding and immune evasion revealed by Lassa nucleocapsid structure. Nature. 2010;468(7325):779-783.

37. Wang X, Li B, Guo Y, et al. Molecular basis for the formation of ribonucleocapsid complex of Crimean-Congo hemorrhagic fever virus. J Struct Biol. 2016;196(3):455-465.

38. Jeeva S, Cheng E, Ganaie SS, Mir MA. Crimean-Congo hemorrhagic fever virus nucleocapsid protein augments mRNA translation. J Virol. 2017;91(15):e00636-17.

39. Wang W, Liu X, Wang X, et al. Structural and functional diversity of nairovirus-encoded nucleoproteins. J Virol. 2015;89(23):11740-11749.

40. Levinston Macleod JM, Marmor H, Garcia-Sastre A, Frias-Staheli N. Mapping of the interaction domains of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J Gen Virol. 2015;96(Pt 3):524-537.

41. Chapman J, Abbott E, Alber DG, et al. RV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother. 2007;51(9):3346-3353.

42. Kao RY, Yang D, Lau LS, et al. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol. 2010;28(6):600-605.

43. Lejal N, Tarus B, Bouguyon E, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57(5):2231-2242.

44. Guardado-Calvo P, Rey FA. The envelope proteins of the Bunyavirales. Adv Virus Res. 2017;98:83-118.

45. Altamura LA, Bertolotti-Ciarlet A, Teijger J, Paragas J, Schmaljohn CS, Doms RW. Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol. 2007;81(12):6632-6642.

46. Strandin T, Hepojoki J, Vaheri A. Cytoplasmic tails of bunyavirus G glycoproteins—Could they act as matrix protein surrogates? Virology. 2015;437(2):73-80.

47. Shi X, Kohl A, Li P, Elliott RM. Role of the cytoplasmic tail domains of Bunyamwera orthobunyavirus glycoproteins Gn and Gc in virus assembly and morphogenesis. J Virol. 2007;81(18):10151-10160.

48. Barski M, Brennan B, Miller OK, et al. Rift Valley fever phlebovirus NSs protein core domain structure suggests molecular basis for nuclear filamentation. Elife. 2017;6:e29236.

49. Leonard VH, Kohl A, Hart TJ, Elliott RM. Interaction of Bunyamwera orthobunyavirus NSs protein with mediator protein MED8: a mechanism for inhibiting the interferon response. J Virol. 2006;80(19):9667-9675.

50. Verbruggen P, Ruf M, Blakgari G, et al. Interferon antagonist NSs of La Crosse virus triggers a DNA damage response-like degradation of transcribing RNA polymerase II. J Biol Chem. 2011;286(5):3681-3692.

51. Jaakelainen KM, Kaukinen P, Minskaya ES, et al. Tula and Puumala hantavirus NSs ORFs are functional and the products inhibit activation of the interferon-betα promoter. J Med Virol. 2007;89(10):1527-1536.

52. Barnwal B, Karlberg H, Mirazimi A, Tan YJ. The non-structural protein of Crimean-Congo hemorrhagic fever virus disrupts the mitochondrial membrane potential and induces apoptosis. J Biol Chem. 2016;291(2):582-592.

53. Terasaki K, Won S, Makino S. The C-terminal region of Rift Valley fever virus NSm protein targets the protein to the mitochondrial outer membrane and exerts antia apoptotic function. J Virol. 2013;87(1):676-682.

54. Kreher F, Tamietti C, Gommet C, et al. The Rift Valley fever accessory proteins NSm and P78/NSm-Gα are distinct determinants of virus propagation in vertebrate and invertebrate hosts. Emerg Microbes Infect. 2014;3(10):e71.

55. Eifan S, Schnettler E, Dietrich I, Kohl A, Blomström AL. Non-structural proteins of arthropod-borne bunyaviruses: roles and functions. Viruses. 2013;5(10):2447-2468.

56. Lucas-Hourani M, Dauzonne D, Jorda P, et al. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog. 2013;9(10):e1003678.

57. Lozach PY, Kühbacher A, Meier JC, et al. DC-SIGN as a receptor for phleboviruses. Cell Host Microbe. 2011;10(1):75-88.

58. Hofmann H, Li X, Zhang X, et al. Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines. J Virol. 2013;87(8):4384-4394.
59. Suda Y, Fukushima S, Tani H, et al. Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system. Arch Virol. 2016;161(6):1447-1454.

60. Léger P, Tetard M, Youness B, et al. Differential use of the C-type lectins L-SIGN and DC-SIGN for phlebovirus endocytosis. Traffic. 2016;17(6):639-656.

61. Goncalves AR, Moraz ML, Pasquato A, Helenius A, Lozach PY, Kunz S. Role of DC-SIGN in Lassa virus entry into human dendritic cells. J Virol. 2013;87(21):11504-11515.

62. Lozach PY, Lortat-Jacob H, de Lacroix de Lavallette A, et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem. 2003;278(22):20358-20366.

63. Lozach PY, Burleigh L, Staropoli I, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem. 2005;280(25):23698-23708.

64. Murakami S, Takenaka-Uema A, Kobayashi T, et al. Heparan sulfate proteoglycan is an important attachment factor for cell entry of Akabane and Schmallenberg viruses. J Virol. 2017;91(15):e00503-17.

65. Mackow ER, Gavrilovskaya IN. Cellular receptors and hantavirus pathogenesis. Curr Top Microbiol Immunol. 2001;256:91-115.

66. Garrison AR, Radoshtizky SR, Kota KP, et al. Crimean-Congo hemorrhagic fever virus utilizes a clathrin- and early endosome-dependent entry pathway. Virology. 2013;444(1-2):45-54.

67. Albornoz A, Hoffmann AB, Lozach PY, Tischler ND. Early bunyavirus-host cell interactions. Viruses. 2016;8(5):143.

68. Santos RI, Rodrigues AH, Silva ML, et al. Oropouche virus entry into Hela cells involves clathrin and requires endosomal acidification. Virus Res. 2008;138(1-2):139-143.

69. Simon M, Johansson C, Mirazimi A. Crimean-Congo hemorrhagic fever virus entry and replication is clathrin-dependent. J Gen Virol. 2009;90( Pt 1):210-215.

70. Cifuentes-Muñoz N, Barriga GP, Valenzuela PD, Tischler ND. Aromatic and polar residues spanning the candidate fusion peptide of the Andes virus Gc protein are essential for membrane fusion and infection. J Gen Virol. 2011;92(Pt 3):552-563.

71. Hover S, Foster B, Fontana J, et al. Bunyavirus requirement for endosomal K+ reveals new roles of cellular ion channels during infection. PloS Pathog. 2018;14(1):e1006845.

72. Bitto D, Hallodorsson S, Caputo A, Huiskoning JT. Low pH and anionic lipid-dependent fusion of Uukuniemi phlebovirus to liposomes. J Biol Chem. 2016;291(12):6412-6422.

73. Kampmann T, Mueller DS, Mark AE, Young PR, Kobe B. The role of histidine residues in low-pH-mediated viral membrane fusion. Structure. 2006;14(10):1481-1487.

74. de Boer SM, Kortekaas J, Spel L, Rottier PJ, Moormann RJ, Bosch BJ. Low pH- and anionic lipid-dependent fusion of two highly pathogenic RNA viruses. J Virol. 2003;77(7):3198-3205.

75. Kampmann T, Mueller DS, Mark AE, Young PR, Kobe B. The role of histidine residues in low-pH-mediated viral membrane fusion. Structure. 2006;14(10):1481-1487.

76. Uemada M, Iwakura Y, Muthusamy S, et al. Heparan sulfate proteoglycans are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem. 2003;278(22):20358-20366.

77. Barriga GP, Villalón-Leletier F, Márquez CL, et al. Inhibition of the hantavirus fusion process by predicted domain III and stem peptides from glycoprotein Gc. PloS Negl Trop Dis. 2016;10(7):e0004799.

78. Dessau M, Modis Y. Crystal structure of glycoprotein C from Rift Valley fever virus. Proc Natl Acad Sci U S A. 2013;110(5):1696-1701.
104. Oestereich L, Rieger T, Neumann M, et al. Evaluation of antiviral efficacy of ribavirin and arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis. 2014;8(5):e2804.

105. Paeshuyse J, Dallmeier K, Neysj J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol. 2011;1(6):590-598.

106. Leysen P, De Clercq E, Neys J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol Pharmacol. 2006;69(4):1461-1467.

107. Arda B, Aciduman A, Johnston JC. A randomized controlled trial of ribavirin in Crimean Congo haemorrhagic fever: ethical considerations. J Med Ethics. 2012;38(2):117-120.

108. Dokuzoguz B, Celikbas AK, Gok SE, Baykam N, Eroglu MN, Ergonul O. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on mortality. Clin Infect Dis. 2013;57(9):1270-1274.

109. Ozbey SB, Kader C, Erbay A, Ergonul O. Early use of ribavirin is beneficial in Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis. 2014;14(4):300-302.

110. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res. 2008;78(1):125-131.

111. Morel ML, Marques-Silva AC, Pimentel VA, da Costa VG. Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis. Virusdisease. 2014;25(3):385-389.

112. Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H. In vitro and in vivo activity of ribavirin against Andes virus infection. PLoS One. 2011;6(8):e23560.

113. Ogg M, Jonsson CB, Camp JV, Hooper JW. Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intra-nasal exposure to Andes virus. Viruses. 2013;5(11):2704-2720.

114. Furuta Y, Komeno T, Nakamura T. Favigapiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463.

115. Nagata T, Lefor AK, Hasegawa M, Ishii M. Favigapiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79-81.

116. Sissoko D, Laouenan C, Folkesson E, et al. Experimental treatment with favigapiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):e1001967.

117. Tani H, Komoto T, Fukuma A, et al. Therapeutic effects of favigapiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration. PLoS One. 2018;13(10):e0206416.

118. Martínez VP, Bellomo C, San Juan J, et al. Person-to-person transmission of Andes virus. Emerg Infect Dis. 2005;11(12):1848-1853.

119. Brown KS, Ebihara H, Feldmann H. Development of a minigenome system for Andes virus, a New World hantavirus. Arch Virol. 2012;157(11):2227-2233.

120. Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB. Antiviral efficacy of favigapiravir against two prominent enzootic agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013;57(10):4673-4680.

121. Wei F, Li JL, Ling JX, et al. Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice. Virus Genes. 2013;46(1):54-62.

122. Flick K, Hooper JW, Schmaljohn CS, Pettersson RF, Feldmann H, Flick R. Rescue of Hantaan virus minigenomes. Virology. 2003;306(2):219-224.

123. Wichmann D, Grone HJ, Frese M, et al. Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice. J Virol. 2002;76(17):8890-8899.

124. Stoltz M, Sundstrom KB, Hidmark A, et al. A model system for in vitro studies of bank vole borne viruses. PLoS One. 2011;6(12):e28992.

125. Seto T, Tkachenko EA, Morozov VG, et al. An efficient in vivo method for the isolation of Puumala virus in Syrian hamsters and the characterization of the isolates from Russia. J Virol Methods. 2011;173(1):17-23.

126. Prescott J, Ye C, Sen G, Hjelle B. Induction of innate immune response genes by Sin Nombre hantavirus does not require viral replication. J Virol. 2005;79(24):15007-15105.

127. Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW. A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus. J Virol. 2014;88(2):811-819.

128. Flick R, Flick K, Feldmann H, Elgh F. Reverse genetics for Crimean-Congo hemorrhagic fever virus. Curr Opin Virol. 2014;7:224-230.
murine model, which has important implications for therapeutic development. *PLoS Negl Trop Dis*. 2013;7(4):e2156.

135. Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. *Antimicrob Agents Chemother*. 2007;51(9):3168-3176.

136. Fisher AF, Tesh RB, Tonry J, Guzman H, Liu D, Xiao SY. Induction of severe disease in hamsters by two sandfly fever group viruses, Punta toro and Gabek Forest (*Phlebovirus, Bunyaviridae*), similar to that caused by Rift Valley fever virus. *Am J Trop Med Hyg*. 2003;69(3):269-276.

137. Mendenhall M, Wong MH, Skirpustonas R, Morrey JD, Gowen BB. Punta Toro virus (*Bunyaviridae, Phlebovirus*) infection in mice: strain differences in pathogenesis and host interferon response. *Virology*. 2009;395(1):143-151.

138. Shimojima M, Fukushi S, Tani H, et al. Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro. *Jpn J Infect Dis*. 2014;67(6):423-427.

139. Brennan B, Li P, Zhang S, et al. Reverse genetics system for severe fever with thrombocytopenia syndrome virus. *J Virol*. 2015;89(6):3026-3037.

140. Tani H, Fukuma A, Fukushi S, et al. Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. *mSphere*. 2016;1(1):e00061-15.

141. Jin C, Liang M, Ning J, et al. Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in *C57/B6* mouse model. *Proc Natl Acad Sci U S A*. 2012;109(25):10053-10058.

142. Brisbarre NM, Plumet S, de Micco P, Leparc-Goffart I, Emonet SF. Toscana virus inhibits the interferon beta response in cell cultures. *Virology*. 2013;442(2):189-194.

143. Gori Savellini G, Di Genova G, Terrosi C, et al. Immunization with Toscana virus N-Gc proteins protects mice against virus challenge. *Virology*. 2008;375(2):521-528.

144. Rezelj VV, Overby AK, Elliott RM. Generation of mutant Uukuniemi viruses lacking the nonstructural protein NSs by reverse genetics indicates that NSs is a weak interferon antagonist. *J Virol*. 2015;89(9):4849-4856.

145. Mazelier M, Rouxel RN, Zumstein M, Mancini R, Bell-Sakyi L, Lozach PY. Uukuniemi virus as a tick-borne virus model. *J Virol*. 2016;90(15):6784-6798.

146. Overby AK, Popov V, Neve EP, Pettersson RF. Generation and analysis of infectious virus-like particles of Uukuniemi virus (*Bunyaviridae*): a useful system for studying bunyaviral packaging and budding. *J Virol*. 2006;80(21):10428-10435.

147. Flick R, Pettersson RF. Reverse genetics system for Uukuniemi virus (*Bunyaviridae*): RNA polymerase I-catalyzed expression of chimeric viral RNAs. *J Virol*. 2001;75(4):1643-1655.

148. Odhiambo C, Venter M, Limbasso K, Swanepoel R, Sang R. Genome sequence analysis of in vitro and in vivo phenotypes of Bunyamwera and Ngari virus isolates from northern Kenya. *PLoS One*. 2014;9(8):e105446.

149. Weber F, Dunn EF, Bridgen A, Elliott RM. The Bunyamwera virus nonstructural protein NSs inhibits viral RNA synthesis in a minireplicon system. *Virology*. 2001;281(1):67-74.

150. Lowen AC, Noonan C, McLees A, Elliott RM. Efficient bunyavirus rescue from cloned cDNA. *Virology*. 2004;330(2):493-500.

151. Borucki MK, Kempf BJ, Blitvich BJ, Blair CD, Beaty BJ. La Crosse virus replication in vertebrate and invertebrate hosts. *Microbes Infect*. 2002;4(3):341-350.

152. Blakori G, Weber F. Efficient cDNA-based rescue of La Crosse bunyaviruses expressing or lacking the nonstructural protein NSs. *J Virol*. 2005;79(16):10420-10428.

153. Livonesi MC, De Sousa RL, Badra SJ, Figueiredo LT. In vitro and in vivo studies of ribavirin action on Brazilian orthobunyavirus. *Am J Trop Med Hyg*. 2006;75(5):1011-1016.

154. Acrani GO, Tilston-Lunel NL, Spiegel M, et al. Establishment of a minigenome system for Oropouche virus reveals the S genome segment to be significantly longer than reported previously. *J Gen Virol*. 2015;96(Pt 3):513-523.

155. Tilston-Lunel NL, Acrani GO, Randall RE, Elliott RM. Generation of recombinant Oropouche viruses lacking the nonstructural protein NSm or NSs. *J Virol*. 2015;90(9):2616-2627.

156. Rodrigues AH, Santos RI, Arisi GM, et al. Oropouche virus experimental infection in the golden hamster (*Mesocricetus auratus*). *Virus Res*. 2011;155(1):35-41.

157. Santos RI, Almeida MF, Paula FE, et al. Experimental infection of suckling mice by subcutaneous inoculation with Oropouche virus. *Virus Res*. 2012;170(1-2):25-33.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: ter Horst S, Conceição-Neto N, Neyts J, Rocha-Pereira J. Structural and functional similarities in bunyaviruses: Perspectives for pan-bunya antivirals. *Rev Med Virol*. 2019;29:e2039. [Link](https://doi.org/10.1002/rmv.2039)